Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 10, 2008 Brian Orelli	Good News for Lucky Men Eli Lilly's erectile dysfunction drug can now be taken daily.
The Motley Fool December 30, 2010 Brian Orelli	That's What You Call Product Differentiation? Endo Pharma misses the mark with its treatment for low testosterone, which the Food and Drug Administration approved yesterday.
The Motley Fool November 30, 2009 Brian Orelli	Anxious No Longer Eli Lilly adds another approval onto Cymbalta.
The Motley Fool November 5, 2010 Brian Orelli	Better Late Than Never for Cymbalta Eli Lilly gets an expanded approval for Cymbalta.
The Motley Fool January 22, 2007 Brian Lawler	Adios, ICOS The pharmaceutical gets finally consumed by Eli Lilly. The deal offered a nice premium to ICOS shareholders. At the same time, it was a good deal for Lilly.
The Motley Fool October 24, 2008 Brian Orelli	Lilly's Results Run the Gamut The company's GAAP EPS and adjusted EPS are at polar extremes.
The Motley Fool January 29, 2009 Brian Orelli	Lilly's in Need of a Pep Pill Eli Lilly's quarterly earnings report was pretty boring. Some drugs were up and others were down -- the end result was flat sales.
The Motley Fool March 23, 2011 Brian Orelli	Eli Lilly: Great Plan, Poor Execution Eli Lilly shuns large mergers, but hasn't produced drugs on its own.
The Motley Fool November 9, 2010 Brian Orelli	Forget R&D; Buy Your Way Into Diagnostics Eli Lilly is expanding its diagnostics business by picking up privately held Avid Radiopharmaceuticals.
The Motley Fool January 5, 2004 Alyce Lomax	Side Effects at Lilly? Growing profits, with earnings pains.
The Motley Fool January 27, 2009 Robert Steyer	Another Angle for Fibromyalgia In the past 18 months, the FDA has approved three drugs that can be used to treat the disease. Which pharma companies will benefit?
The Motley Fool January 28, 2010 Brian Orelli	The Biggest Development-Stage Drugmaker, Ever Eli Lilly seems to have a lot more in common with its development-stage little brothers than it does with its big pharma brethren.
The Motley Fool December 10, 2009 Brian Orelli	A Tale of Two Lillys It was the best of times, it was the worst of times. Dickens could have been talking about Eli Lilly which has a tale of two cities all on its own.
The Motley Fool December 31, 2008 Brian Orelli	An Imminent Drug Approval? Really? Lilly may finally hear about prasugrel.
The Motley Fool July 6, 2009 Brian Orelli	Lilly Shows Us How It's Done The company announces that the Food and Drug Administration had expanded the approval of its cancer drug, Alimta, to include maintenance therapy for nonsquamous, non-small cell lung cancer.
The Motley Fool September 30, 2010 Brian Orelli	Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers.
The Motley Fool October 17, 2006 Brian Lawler	Lilly Doesn't Like Sharing Profits The company is buying out ICOS Corporation, its partner in erectile-dysfunction drug Cialis. Investors, take note.
The Motley Fool March 18, 2011 Brian Orelli	Forget Getting Approved, for Now The FDA wants more information on Eli Lilly's Amyvid.
The Motley Fool March 24, 2005 Brian Gorman	Eli Lilly Turns to Japan The company's move to focus more resources on Japan makes good sense.
The Motley Fool July 23, 2010 Brian Orelli	Eli Lilly Looks Great Today, but I'm Concerned About Tomorrow Eli Lilly is firing on all cylinders, but is there a blowout in its future?
The Motley Fool January 5, 2010 Brian Orelli	Lilly's Effient: Cheap Enough, for Now In order to justify the use of Effient, Eli Lilly is touting a study published in today's Circulation demonstrating the cost effectiveness of Effient over Plavix.
The Motley Fool October 21, 2010 Brian Orelli	Nice Earnings, Eli Lilly, but ... Eli Lilly trounced analysts' earnings estimates today, but investors sighed -- and for good reason.
The Motley Fool July 13, 2004 Brian Gorman	The "Cialis Promise" Eli Lilly and Icos are offering a free trial of their drug Cialis for men who have never used it before and promise that participants not pleased with the results will receive a voucher for a competing product.
The Motley Fool January 30, 2008 Brian Lawler	Eli Lilly Is Resilient Proving that not every sector is affected by downturns, Eli Lilly released its fourth-quarter results yesterday, showing a bit of top-line growth.
The Motley Fool August 19, 2009 Brian Orelli	Them's the Breaks for Lilly The drugmaker cuts its losses after a disappointing trial on an osteoporosis drug.
The Motley Fool October 22, 2007 Brian Lawler	Modest Numbers From Eli Lilly Its sales were up for the quarter, but a new drug might be the best indicator of its prospects. Lilly's pipeline will dictate its near-term future.
The Motley Fool October 20, 2006 Brian Lawler	Lilly Pads Its Earnings Lilly reports third-quarter 2006 numbers and gobbles up Cialis. Investors, take note.
The Motley Fool October 21, 2004 Roger Nusbaum	Pictures of Lilly Eli Lilly's numbers get lost in the wake of Merck and Pfizer. While the market waits for drug stocks to recover, investors can collect Lilly's 2.5%, safe, dividend.
The Motley Fool September 5, 2007 Billy Fisher	Lilly's Pipeline Continues to Produce Another schizophrenia drug from the company shows promise in a clinical trial, prompting the company to plan additional trials. This is the latest good news in what has been a good year for Lilly.
The Motley Fool May 24, 2011 Brian Orelli	If at First You Don't Succeed, Spin It Off Eli Lilly ditches Xigris by spinning off BioCritica.
The Motley Fool April 19, 2004 Alyce Lomax	Eli Lilly's Drug Dependency Competitive concerns make Cymbalta and new drugs more important than ever.
The Motley Fool August 17, 2010 Brian Orelli	Forget About This Drug Saving the Company Lilly's Alzheimer's drug fails hard.
The Motley Fool December 22, 2009 Brian Orelli	Some Incyte Into Why These Drugs Rock Eli Lilly jumps on the oral-drug-for-rheumatoid-arthritis bandwagon.
The Motley Fool April 15, 2005 Brian Gorman	Relief Pitch for Eli Lilly A ruling upholding the Zyprexa patent is good news for Lilly, but promising drugs in the pipeline are even more encouraging. Investors, take note.
The Motley Fool December 14, 2010 Brian Orelli	Another Mishap for a Drugmaker That Can't Afford It Eli Lilly puts cancer drug tasisulam on a clinical hold.
The Motley Fool February 25, 2009 Brian Orelli	Pfizer Doesn't Like Reruns The company drops two drugs that had made it as far as phase 3 trials.
The Motley Fool August 20, 2010 Brian Orelli	Depression Is Painful. Advisory Panels More So. Eli Lilly's Cymbalta has a rough time in from of the panel of experts.
BusinessWeek February 28, 2005 David Kiley	The Little Blue Pill -- And Pals -- Have The Blues Despite gargantuan ad budgets, sales are trailing expectations for all three erectile dysfunction contenders.
The Motley Fool March 23, 2009 Brian Orelli	Good News for Eli Lilly's Depression Drug Eli Lilly announces that the Food and Drug Administration has expanded the label of Symbyax to treat patients with treatment-resistant depression, meaning they haven't been helped by at least two other drugs.
The Motley Fool August 18, 2010 Brian Orelli	More Pain Ahead for Eli Lilly? An advisory panel meeting tomorrow could further the company's slide.
The Motley Fool October 22, 2007 Brian Orelli	New Warnings Won't Sink ED Drug Sales Shockingly, new safety warnings won't hurt erectile dysfunction drugs. Any investor jumpiness should be looked at as a buying opportunity for smart investors.
The Motley Fool March 27, 2008 Brian Lawler	Eli Lilly Hands Over Cold Cash Lilly loses to the state of Alaska in a courtroom battle over its top drug Zyprexa.
The Motley Fool January 16, 2009 Brian Orelli	Lilly Pays Up. Big Deal. Lawsuits are just a fact of life when investing in drug companies, and pharmaceutical investors have to expect these kinds of legal defeats.
The Motley Fool April 22, 2008 Brian Lawler	Lilly in Full Financial Bloom Pharmaceutical Eli Lilly boosts revenue in the first quarter, but its drug-pipeline progress falls short of spectacular.
The Motley Fool December 9, 2008 Brian Orelli	The FDA Can't See the Forest or the Trees Forest Laboratories and Cypress Bioscience are still waiting for FDA approval, but now they've got more data to prove their point.
The Motley Fool April 27, 2011 Brian Orelli	Don't Get Pumped Up About Pumping It In Medtronic and Eli Lilly team up against Parkinson's.
The Motley Fool December 22, 2006 Stephen Albainy-Jenei	Is Off-Label Off-Base? Off-label prescriptions for uses lacking scientific support account for billions in drug revenue for Eli Lilly. If the FDA takes an aggressive stance on off-label-use marketing, it could significantly shrink drug sales for companies whose revenues are derived largely from such off-label use.
The Motley Fool October 7, 2008 Brian Orelli	Eli Lilly's Risky Gamble Eli Lilly is desperate, and the high acquisition price of ImClone shows it.
The Motley Fool July 10, 2008 Brian Lawler	Lilly Targets a Tiny Prize As drugmakers go, this acquisition's a value meal.
The Motley Fool June 30, 2004 Alyce Lomax	A Monster Drug for Lilly? The drug giant files a new drug application (NDA) for its experimental new drug for diabetics.